A traditional view of separate therapies for diabetes and CVD was challenged after large randomized controlled trials demonstrated CV benefits for two classes of drugs, SGLT2 inhibitors and GLP-1 receptor agonists, which are “arguably both diabetes and cardiovascular drugs,” Gregory G. Schwartz, professor of medicine at the University of Colorado School of Medicine and chief of the cardiology section at Rocky Mountain Regional VA Medical Center in Aurora, Colorado, said during a presentation at the American Society for Preventive Cardiology Congress on CVD Prevention.